Exceedingly Small Gadolinium Oxide Nanoparticles with Remarkable Relaxivities for Magnetic Resonance Imaging of Tumors. Issue 41 (25th August 2019)
- Record Type:
- Journal Article
- Title:
- Exceedingly Small Gadolinium Oxide Nanoparticles with Remarkable Relaxivities for Magnetic Resonance Imaging of Tumors. Issue 41 (25th August 2019)
- Main Title:
- Exceedingly Small Gadolinium Oxide Nanoparticles with Remarkable Relaxivities for Magnetic Resonance Imaging of Tumors
- Authors:
- Shen, Zheyu
Fan, Wenpei
Yang, Zhen
Liu, Yijing
Bregadze, Vladimir I.
Mandal, Swadhin K.
Yung, Bryant C.
Lin, Lisen
Liu, Ting
Tang, Wei
Shan, Lingling
Liu, Yuan
Zhu, Shoujun
Wang, Sheng
Yang, Weijing
Bryant, L. Henry
Nguyen, Duong T.
Wu, Aiguo
Chen, Xiaoyuan - Abstract:
- Abstract: Gd chelates have occupied most of the market of magnetic resonance imaging (MRI) contrast agents for decades. However, there have been some problems (nephrotoxicity, non‐specificity, and low r 1 ) that limit their applications. Herein, a wet‐chemical method is proposed for facile synthesis of poly(acrylic acid) (PAA) stabilized exceedingly small gadolinium oxide nanoparticles (ES‐GON‐PAA) with an excellent water dispersibility and a size smaller than 2.0 nm, which is a powerful T 1 ‐weighted MRI contrast agent for diagnosis of diseases due to its remarkable relaxivities ( r 1 = 70.2 ± 1.8 mM −1 s −1, and r 2 / r 1 = 1.02 ± 0.03, at 1.5 T). The r 1 is much higher and the r 2 / r 1 is lower than that of the commercial Gd chelates and reported gadolinium oxide nanoparticles (GONs). Further ES‐GON‐PAA is developed with conjugation of RGD2 (RGD dimer) (i.e., ES‐GON‐PAA@RGD2) for T 1 ‐weighted MRI of tumors that overexpress RGD receptors (i.e., integrin αv β 3 ). The maximum signal enhancement (ΔSNR) for T 1 ‐weighted MRI of tumors reaches up to 372 ± 56% at 2 h post‐injection of ES‐GON‐PAA@RGD2, which is much higher than commercial Gd‐chelates (<80%). Due to the high biocompatibility and high tumor accumulation, ES‐GON‐PAA@RGD2 with remarkable relaxivities is a promising and powerful T 1 ‐weighted MRI contrast agent. Abstract : Poly(acrylic acid) (PAA) stabilized exceedingly small gadolinium oxide nanoparticles (ES‐GON‐PAA) can be used for high contrast T 1 ‐weightedAbstract: Gd chelates have occupied most of the market of magnetic resonance imaging (MRI) contrast agents for decades. However, there have been some problems (nephrotoxicity, non‐specificity, and low r 1 ) that limit their applications. Herein, a wet‐chemical method is proposed for facile synthesis of poly(acrylic acid) (PAA) stabilized exceedingly small gadolinium oxide nanoparticles (ES‐GON‐PAA) with an excellent water dispersibility and a size smaller than 2.0 nm, which is a powerful T 1 ‐weighted MRI contrast agent for diagnosis of diseases due to its remarkable relaxivities ( r 1 = 70.2 ± 1.8 mM −1 s −1, and r 2 / r 1 = 1.02 ± 0.03, at 1.5 T). The r 1 is much higher and the r 2 / r 1 is lower than that of the commercial Gd chelates and reported gadolinium oxide nanoparticles (GONs). Further ES‐GON‐PAA is developed with conjugation of RGD2 (RGD dimer) (i.e., ES‐GON‐PAA@RGD2) for T 1 ‐weighted MRI of tumors that overexpress RGD receptors (i.e., integrin αv β 3 ). The maximum signal enhancement (ΔSNR) for T 1 ‐weighted MRI of tumors reaches up to 372 ± 56% at 2 h post‐injection of ES‐GON‐PAA@RGD2, which is much higher than commercial Gd‐chelates (<80%). Due to the high biocompatibility and high tumor accumulation, ES‐GON‐PAA@RGD2 with remarkable relaxivities is a promising and powerful T 1 ‐weighted MRI contrast agent. Abstract : Poly(acrylic acid) (PAA) stabilized exceedingly small gadolinium oxide nanoparticles (ES‐GON‐PAA) can be used for high contrast T 1 ‐weighted magnetic resonance imaging of tumors because of their exceedingly small particle size (<2 nm), and remarkable relaxivities ( r 1 = 70.2 ± 1.8 mM −1 s −1, and r 2 / r 1 = 1.02 ± 0.03, 1.5 T) at high PAA/Gd molar ratio. … (more)
- Is Part Of:
- Small. Volume 15:Issue 41(2019)
- Journal:
- Small
- Issue:
- Volume 15:Issue 41(2019)
- Issue Display:
- Volume 15, Issue 41 (2019)
- Year:
- 2019
- Volume:
- 15
- Issue:
- 41
- Issue Sort Value:
- 2019-0015-0041-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2019-08-25
- Subjects:
- contrast agents -- exceedingly small gadolinium oxide nanoparticles -- magnetic resonance imaging -- remarkable relaxivities -- tumors
Nanotechnology -- Periodicals
Nanoparticles -- Periodicals
Microtechnology -- Periodicals
620.5 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1613-6829 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/smll.201903422 ↗
- Languages:
- English
- ISSNs:
- 1613-6810
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8309.952000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14246.xml